Standard treatments helped many people with myasthenia gravis (MG) who lack the most common disease-causing antibodies, according to a new review study. The findings shed new light on how so-called double-seronegative MG (dSNMG) compares with more common forms of the disease and highlight the need for careful monitoring,…
News
Tofacitinib, an approved medication for some types of inflammatory arthritis and inflammatory bowel disease, improves muscle strength, daily functioning, and quality of life in people with hard-to-treat myasthenia gravis (MG), according to a small pilot clinical trial. Slightly more than half of the participants experienced few or no symptoms…
A new digital platform — MyaLink — enables doctors to monitor the physical and mental health of people with myasthenia gravis (MG) in real time and communicate directly with patients through the app, a study shows. Data collected by MyaLink on MG patients’ symptoms, disease activity, daily functioning, and…
Robotic thymectomy — a surgical removal of the thymus gland using robotic systems — is an effective and safe treatment for people with late-onset myasthenia gravis (MG), including those who develop the rare neuromuscular disease after the age of 65, according to a two-decade-long study in China. Rates…
A single course of six once-weekly infusions of Descartes-08, an investigational CAR T-cell therapy, was well tolerated and resulted in sustained clinically meaningful responses in people with generalized myasthenia gravis (gMG). That’s according to final data from the Phase 2b MG-001 clinical trial (NCT04146051), which also showed…
People with myasthenia gravis (MG) who take corticosteroids, especially at higher cumulative doses, face an increased risk of developing other health conditions, according to a study in the U.S. Patients are at risk for conditions including diabetes, infections, and cardiovascular diseases, the researchers found. “Our findings highlight the importance…
A new study shows how Cour Pharmaceuticals‘ nanoparticle platform is able to modulate immune system activity, lending support for the company’s experimental treatments. Cour’s CNP-106, an experimental treatment for generalized myasthenia gravis, is currently being tested in a Phase 1b/2a clinical trial (NCT06106672), which may still be…
An elevated triglyceride-glucose (TyG) index, a blood marker of insulin resistance, may be a useful biomarker to identify people at risk of developing myasthenia gravis (MG) associated with a thymoma, or thymus tumor, a study suggested. Insulin resistance refers to the body’s impaired response to insulin, a hormone that…
Telitacicept safely and effectively reduces disease severity in people with generalized myasthenia gravis (MG) associated with anti-AChR antibodies, including when the disease is hard to treat or associated with a thymus tumor, a small study in China showed. “Clinical outcomes showed increased efficacy of telitacicept when used earlier…
About half of people with myasthenia gravis (MG) experience symptoms of urinary incontinence, while about one-third have signs of an overactive bladder, with an urgent need to urinate. That’s according to a recent study in Israel, which also found that patients with late-onset MG had a higher prevalence of…
Recent Posts
- With his symptoms easing due to cold weather, my brother seizes the day
- How I build a career with a body that has limits due to MG
- Standard treatments help many people with rare double-seronegative MG
- Arthritis drug tofacitinib may be effective for hard-to-treat MG: Study
- New MG app helps doctors track symptoms between clinic visits